Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2009

01-07-2009 | Gastrointestinal Oncology

Prophylactic Total Gastrectomy (PTG) for Hereditary Diffuse Gastric Cancer (HDGC): The Newfoundland Experience with 23 Patients

Authors: P. C. Hebbard, MD, A. MacMillan, MS, D. Huntsman, MD, P. Kaurah, MSc, F. Carneiro, PhD, X. Wen, MD, A. Kwan, MD, D. Boone, MD, F. Bursey, MD, J. Green, PhD, B. Fernandez, MD, D. Fontaine, MD, D. A. Wirtzfeld, MD

Published in: Annals of Surgical Oncology | Issue 7/2009

Login to get access

Abstract

Background

Hereditary diffuse gastric cancer (HDGC) results from truncating mutations of the CDH1 (E-cadherin) gene. It is an autosomal dominant cancer susceptibility syndrome with a lifetime risk of diffuse gastric cancer (DGC) of 60–80%, with a mean age of onset of 37 years. There exists no adequate screening test for DGC. Early intramucosal diffuse/signet-ring cell carcinomas have been found in prophylactic total gastrectomy (PTG) specimens following normal preoperative endoscopy. Total gastrectomy has been advocated on a prophylactic basis. The aim of this study was to report our experience with PTG in 23 patients from the Canadian province of Newfoundland and Labrador. This is the largest series worldwide.

Methods

A retrospective study of consecutive patients undergoing PTG for HDGC was performed. All patients were confirmed to have a truncating mutation of the CDH1 gene.

Results

Twenty-three patients underwent PTG between February 2006 and November 2008. Major complications were found in 4/23 patients (17%), with no mortality. Two of 23 patients (9%) had positive mucosal biopsies on preoperative EGD. Twenty-two of 23 patients (96%) had evidence of diffuse/signet-ring carcinoma on final standardized pathological evaluation. Therefore, 21/23 (91%) were not picked up by preoperative EGD screening.

Conclusions

PTG can be performed in patients with HDGC with a low rate of serious complications. Methods of reconstruction incorporating a pouch reservoir and preservation of the postgastric branches of the vagus nerves need to be explored. More refined penetrance estimates, effective screening protocols, and long-term psychological and functional outcomes following PTG require organized multicenter collaborative efforts.
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–6.PubMedCrossRef
2.
Lauren P. The two histological types of gastric carcinomas: diffuse and so-called intestinal-type carcinoma. An attempt at histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed
3.
Henson DE, Dittus C, Younes M, et al. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med. 2004;128:765–70.PubMed
4.
Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev. 1986;8:1–27.PubMed
5.
Ekstrom AM, Serafini M, Nyren O, et al. Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden. Int J Cancer. 2000;87:133–40.PubMedCrossRef
6.
Palli D, Galli M, Caporaso NE, et al. Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev. 1994;3:15–8.PubMed
7.
Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402–5.PubMedCrossRef
8.
Suriano G, Yew S, Ferreira P, et al. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res. 2005;11:5401–9.PubMedCrossRef
9.
Kaurah P, MacMillan A, Boyd, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007;297:2360–72.PubMedCrossRef
10.
Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999;36:873–80.PubMed
11.
Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004;41:508–17.PubMedCrossRef
12.
Blair V, Martin I, Shaw D, et al. Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol. 2006;4:262–75.PubMedCrossRef
13.
Barber M, Fitzgerald RC, Caldas C. Familial gastric cancer—aetiology and pathogenesis. Best Practice Res Clin Gastroenterol. 2006;20:721–34.CrossRef
14.
Carneiro F, Oliveira C, Suriano G, Seruca R. Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. J Clin Pathol. 2008;61:25–30.PubMedCrossRef
15.
Pharoah PD, Guilford P, Caldas C for the International Gastric Cancer linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348–53.PubMedCrossRef
16.
Hamy A, Letessier E, Bizouam P, et al. Study of survival and prognostic factors in patients undergoing resection for gastric linitis plastica: a review of 86 cases. Int Surg. 1999;84:337–43.PubMed
17.
Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. NEJM. 2001;344:1904–9.PubMedCrossRef
18.
Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004;203:681–7.PubMedCrossRef
19.
Barber M, Save C, Carneiro F, et al. Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. J Pathol. 2008;216:286–94.PubMedCrossRef
20.
Norton JA, Ham CM, Dam JV, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg. 2007;245:873–79.PubMedCrossRef
21.
Lynch HT, Kaurah P, Wirtzfeld D, et al. Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer. 2008;112:2655–63.PubMedCrossRef
22.
Moran CJ, Joyce M, McAnena OJ. CDH1 associated gastric cancer: a report of a family and review of the literature. Eur J Surg Oncol. 2005;31:259–64.PubMedCrossRef
23.
Lynch HT, Silva A, Wirtzfeld D, et al. Hereditary diffuse gastric cancer: prophylactic surgical oncology implications. Surg Clin North Am. 2008;88:759–78.PubMedCrossRef
24.
Richards FM, McKee SA, Rajput MH, et al. Germline E-cadherin gene (CDH1) mutations define an inherited cancer syndrome dominate by diffuse gastric cancer. Human Mol Genet. 1999;14:249–55.
25.
Charlton A, Blair V, Shaw D, et al. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut. 2004;53:814–20.PubMedCrossRef
26.
Rogers WM, Dobo E, Norton JA, et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol. 2008;32:799–809.PubMedCrossRef
27.
Shaw D, Blair V, Framp A, et al. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut. 2005;54:461–68.PubMedCrossRef
28.
van Kouwen MCA, Drenth JPH, Oyen WJG, et al. [18F]Fluoro-2-deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. Clin Cancer Res. 2004;10:6456–9.PubMedCrossRef
29.
Nunobe S, Hiki N, Fukunaga T, et al. Laparoscopy-assisted pylorus-preserving gastectomy: preservation of vagus nerve and infrapyloric blood flow induces less stasis. World J Surg. 2007;31:2335–40.PubMedCrossRef
30.
Ando S, Tsuji H. Surgical technique of vagus nerve-preserving gastrectomy with D2 lymphadenectomy for gastric cancer. ANZ J Surg. 2008;78:172–6.PubMedCrossRef
31.
Fein M, Fuchs K, Thalheimer A, et al. Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy. Ann Surg. 2008;247:759–65.PubMedCrossRef
Metadata
Title
Prophylactic Total Gastrectomy (PTG) for Hereditary Diffuse Gastric Cancer (HDGC): The Newfoundland Experience with 23 Patients
Authors
P. C. Hebbard, MD
A. MacMillan, MS
D. Huntsman, MD
P. Kaurah, MSc
F. Carneiro, PhD
X. Wen, MD
A. Kwan, MD
D. Boone, MD
F. Bursey, MD
J. Green, PhD
B. Fernandez, MD
D. Fontaine, MD
D. A. Wirtzfeld, MD
Publication date
01-07-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0471-z

Other articles of this Issue 7/2009

Annals of Surgical Oncology 7/2009 Go to the issue

Gastrointestinal Oncology

Epigenetics in Gastric Cancer: Challenges for Clinical Implications

Hepatobiliary and Pancreatic Tumors

Perioperative Factors Affecting Long-Term Outcomes of 473 Consecutive Patients Undergoing Hepatectomy for Hepatocellular Carcinoma

Translational Research and Biomarkers

Dickkopf-1 Expression as a Marker for Predicting Clinical Outcome in Esophageal Squamous Cell Carcinoma

Gastrointestinal Oncology

Genetic Susceptibility to Gastrointestinal Cancer: Minireview of the Genomewide Studies

Gastrointestinal Oncology

Synchronous Colorectal Liver Metastases: Triumph Of Prospective Randomized Trials Over Observational Bias Leads To Paradigm Shift

Urologic Oncology

Caspase 9 and Caspase 8 Gene Polymorphisms and Susceptibility to Bladder Cancer in North Indian Population